Exact Sciences Co. (NASDAQ:EXAS) insider Jacob A. Orville sold 1,696 shares of the company’s stock in a transaction dated Friday, February 19th. The shares were sold at an average price of $143.38, for a total transaction of $243,172.48.
EXAS stock traded down $5.49 during mid-day trading on Monday, hitting $142.32. 1,445,208 shares of the company were exchanged, compared to its average volume of 1,923,244. The company has a debt-to-equity ratio of 0.68, a quick ratio of 6.04 and a current ratio of 6.35. Exact Sciences Co. has a 1-year low of $35.25 and a 1-year high of $159.54. The firm’s 50 day simple moving average is $142.80 and its 200 day simple moving average is $115.07. The firm has a market cap of $24.07 billion, a P/E ratio of -66.88 and a beta of 1.64.
Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Monday, February 15th. The medical research company reported ($2.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($2.60). Exact Sciences had a negative return on equity of 11.71% and a negative net margin of 25.27%. On average, equities research analysts predict that Exact Sciences Co. will post -1.56 EPS for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. City Holding Co. bought a new stake in shares of Exact Sciences in the fourth quarter valued at about $26,000. Adirondack Trust Co. acquired a new stake in Exact Sciences in the 4th quarter valued at approximately $31,000. Wolff Wiese Magana LLC bought a new stake in Exact Sciences in the 4th quarter valued at approximately $34,000. Bessemer Group Inc. acquired a new position in Exact Sciences during the 4th quarter worth approximately $37,000. Finally, Montag A & Associates Inc. bought a new position in shares of Exact Sciences during the 4th quarter worth approximately $43,000. 90.39% of the stock is currently owned by hedge funds and other institutional investors.
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services.
Featured Article: What is total return in investing?
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.